Lilly oral GLP‑1 pill shows strong weight loss
Eli Lilly’s once-daily oral GLP‑1 drug orforglipron produced significant weight loss and cardiometabolic benefits over 72 weeks in a phase 3 trial published in the New England Journal of Medicine, with safety similar to injectable GLP‑1s. Lilly says it will seek U.S. approval for obesity as early as 2026 and plans to pursue a type 2 diabetes indication the same year, as analysts suggest the pill could reduce reliance on costly injectables.
Health
Science
📰 Sources (1)
Weight loss could be just a pill away, study of new medication suggests
New information:
- At the highest dose, participants lost an average 27.3 lb; ~60% lost ≥10% body weight and 39.6% lost ≥15%.
- Among 1,127 participants with prediabetes, up to 91% achieved near-normal glycemia vs 42% on placebo.
- Improvements included non‑HDL cholesterol, systolic blood pressure, triglycerides, and a 47.7% drop in high‑sensitivity CRP at the top dose; GI side effects were the most common.